FWM
VRTX icon

Focused Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Focused Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,000
Closed -$17K – 911
2020
Q3 		$17K Buy
+1,000
New +$276K ﹤0.01% 445
2014
Q3 		– Sell
-12
Closed -$15K – 721
2014
Q2 		$15K Buy
+12
New +$841 0.01% 363

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Focused Wealth Management's VRTX Position: Q1 2024 in Review

Focused Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 53 shares — an estimated $21.6K sold.

Focused Wealth Management first reported a position in VRTX in Q3 2013 and held it in 36 quarters. The position peaked at $120K in Q2 2014. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Focused Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Focused Wealth Management sold 53 Vertex Pharmaceuticals shares in Q1 2024, an estimated $21.6K.
  • Focused Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 36 quarters.
  • Focused Wealth Management's Vertex Pharmaceuticals position peaked at $120K in Q2 2014.
  • 1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.